English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, November 30, 2021
中国抗体公布旗舰产品SM03完成在中国III期临床试验招募
中國抗體公佈旗艦產品SM03完成在中國III期臨床試驗招募
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Friday, November 26, 2021
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
Thursday, November 25, 2021
中国抗体受邀出席首届亚洲医疗健康高峰论坛
中國抗體受邀出席首屆亞洲醫療健康高峰論壇
Thursday, November 18, 2021
重磅!B细胞CD22单抗SM03治疗类风湿关节炎临床研究结果最新公布!
Friday, September 17, 2021
中国抗体、信诺维与云顶新耀宣布签署新一代BTK抑制剂SN1011肾病领域的全球开发及商业化的授权协议
中國抗體、信諾維與雲頂新耀宣佈簽署新一代BTK抑制劑SN1011腎病領域的全球開發及商業化的授權協議
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575